Alembic Pharmaceuticals Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Alembic Pharmaceuticals Limited Pharmaceutical Export Portfolio Dataset — 37 Products, $127.6M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Alembic Pharmaceuticals Limited — Pharmaceutical Exporter Profile (2026) | 37 Products, $127.6M Trade | TransData Nexus

Alembic Pharmaceuticals Limited

Indian Pharmaceutical Exporter · Cardiovascular Specialist · $127.6M Total Trade · DGFT Verified

Alembic Pharmaceuticals Limited is an Indian pharmaceutical exporter with a total trade value of $127.6M across 37 products in 16 therapeutic categories. Based on 3,520 verified export shipments from Indian Customs (DGFT) records, Alembic Pharmaceuticals Limited is the #1 Indian exporter in 1 product including . Top exports include Celecoxib ($12.2M), Losartan ($11.1M), Telmisartan ($11.0M).

Alembic Pharmaceuticals Limited — Export Portfolio & Destination Treemap

Alembic Pharmaceuticals Limited pharmaceutical export portfolio — 37 products across 16 therapeutic categories. Source: Indian Customs (DGFT).

Who is Alembic Pharmaceuticals Limited? — Company Overview & Market Position

Alembic Pharmaceuticals Limited, established in 1907, is a leading Indian multinational pharmaceutical company headquartered in Vadodara, Gujarat. The company specializes in the development, manufacturing, marketing, and sale of pharmaceutical products, including active pharmaceutical ingredients (APIs) and finished dosage formulations. Alembic's product portfolio spans various therapeutic areas such as cardiology, dermatology, diabetes, ophthalmology, and infectious diseases. In fiscal year 2025, the company reported a revenue of ₹6,672 crore (approximately $797.4 million), marking a 7.1% increase from the previous year. The net income for the same period was ₹583.42 crore (approximately $70.5 million), reflecting a 5.3% decrease compared to the prior year. As of 2025, Alembic Pharmaceuticals employed 16,571 individuals. The company's stock is listed on the Bombay Stock Exchange (BSE) under the ticker symbol 533573 and on the National Stock Exchange of India (NSE) under APLLTD.

What Does Alembic Pharmaceuticals Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Celecoxib$12.2M 2

Product Portfolio — Top 30 by Export Value

Alembic Pharmaceuticals Limited exports 37 pharmaceutical products across 16 therapeutic categories. Market leader (#1 exporter) in 1 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Celecoxib	Analgesics & Antipyretics	$12.2M	434	9.1%	3
2	Losartan	Cardiovascular	$11.1M	222	3.7%	5
3	Telmisartan	Cardiovascular	$11.0M	251	0.1%	5
4	Valsartan	Cardiovascular	$10.5M	270	5.3%	4
5	Azithromycin	Antibiotics	$8.7M	174	4.7%	4
6	Irbesartan	Cardiovascular	$7.6M	189	7.2%	5
7	Doxycycline	Antibiotics	$7.0M	141	5.9%	3
8	Metoprolol	Cardiovascular	$6.6M	234	0.8%	9
9	Fluoxetine	CNS & Psychiatric	$5.8M	261	2.5%	6
10	Dapagliflozin	Advanced Diabetes Medications	$4.8M	95	9.6%	3
11	Famotidine	Gastrointestinal	$4.3M	124	7.7%	4
12	Clonazepam	CNS & Psychiatric	$3.9M	105	3.0%	2
13	Metronidazole	Advanced Antibiotics	$3.6M	72	1.8%	6
14	Ketorolac	Analgesics & Antipyretics	$3.5M	70	3.0%	4
15	Hydrochlorothiazide	Diuretics	$3.1M	78	0.8%	15
16	Febuxostat	Lipid & Metabolism	$2.8M	56	5.7%	3
17	Paclitaxel	Oncology	$2.2M	44	2.6%	8
18	Oseltamivir	Antivirals	$2.0M	41	1.5%	9
19	Fluorouracil	Oncology	$1.9M	39	15.9%	2
20	Diclofenac	Analgesics & Antipyretics	$1.9M	38	0.5%	14
21	Fenofibrate	Lipid & Metabolism	$1.5M	129	2.0%	11
22	Rivaroxaban	Cardiovascular	$1.3M	38	2.4%	10
23	Leflunomide	Immunosuppressants	$1.2M	87	7.8%	5
24	Mesalamine	Gastrointestinal	$1.1M	38	0.1%	11
25	Dapsone	Antimalarial & Antiparasitic	$1.0M	20	4.4%	3
26	Nystatin	Antifungals	$988.1K	79	1.9%	9
27	Cyclophosphamide	Oncology	$850.4K	30	4.4%	3
28	Itraconazole	Antifungals	$804.4K	48	2.9%	10
29	Docetaxel	Oncology	$700.0K	14	1.8%	7
30	Moxifloxacin	Advanced Antibiotics	$683.8K	25	2.1%	8

Alembic Pharmaceuticals Limited exports 37 pharmaceutical products across 16 therapeutic categories with a total export value of $127.6M. The company is the #1 Indian exporter in 1 product: . The top category is Cardiovascular (37.9% of portfolio), followed by Analgesics & Antipyretics (13.8%), reflecting a diversified portfolio where the top 5 products account for only 41.9% of total value.

Showing top 30 of 37 products. Contact us for complete data.

Alembic Pharmaceuticals Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Alembic Pharmaceuticals operates multiple manufacturing facilities across India, including locations in Gujarat (Panelav and Karakhadi), Sikkim, and Pithampur. These facilities are equipped to produce a wide range of pharmaceutical products, including oral solids, injectables, and ophthalmic formulations. The company's manufacturing plants adhere to current Good Manufacturing Practice (cGMP) standards and have received approvals from various international regulatory agencies, ensuring the production of high-quality pharmaceutical products.

3Key Leadership

The leadership team at Alembic Pharmaceuticals is headed by Chairman and CEO Chirayu Ramanbhai Amin. Pranav Chirayu Amin serves as the Managing Director, while Shaunak Chirayu Amin also holds the position of Managing Director. Raj Kumar Baheti is the Chief Financial Officer and Director of Finance. This executive team is responsible for steering the company's strategic direction and overseeing its operations in the pharmaceutical industry.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Alembic Pharmaceuticals Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Alembic Pharmaceuticals has established a significant presence in regulated markets, particularly in the United States. Between 2024 and 2025, the company secured multiple final and tentative approvals from the U.S. Food and Drug Administration (FDA) for generic medicines. Notably, in December 2024, Alembic received tentative approval for Olopatadine Hydrochloride Ophthalmic Solution 0.7%, a generic version of Pataday Once Daily Relief. In May 2025, the company obtained final approval for Rivaroxaban tablets in various strengths, therapeutically equivalent to Xarelto. Additionally, in June 2025, Alembic received final approval for Doxorubicin Hydrochloride Liposome Injection, a generic version of Doxil, indicated for certain cancers. These approvals underscore Alembic's commitment to expanding its footprint in the U.S. market. The company's products are also available in other regulated markets, including the European Union, the United Kingdom, Australia, and Japan, where they comply with respective regulatory standards.

2Emerging Markets

Alembic Pharmaceuticals has strategically expanded its presence in emerging markets, including Africa, Latin America, and Southeast Asia. The company's adherence to World Health Organization (WHO) prequalification standards has facilitated access to these regions, enabling the supply of quality-assured pharmaceutical products. This commitment to international standards has bolstered Alembic's reputation and market share in these emerging markets.

Alembic Pharmaceuticals Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Alembic Pharmaceuticals has a robust relationship with the U.S. Food and Drug Administration (FDA), evidenced by multiple approvals for its Abbreviated New Drug Applications (ANDAs). Between 2024 and 2025, the company received approvals for several generic medicines, including Olopatadine Hydrochloride Ophthalmic Solution 0.7%, Rivaroxaban tablets, Doxorubicin Hydrochloride Liposome Injection, and Tretinoin Cream USP 0.025%. These approvals highlight Alembic's commitment to meeting FDA standards and expanding its product offerings in the U.S. market. The company's facilities are registered with the FDA, and its products are subject to regular inspections to ensure compliance with U.S. regulatory requirements.

2WHO & EU GMP

Alembic Pharmaceuticals' manufacturing facilities adhere to Good Manufacturing Practice (GMP) standards set by the World Health Organization (WHO) and the European Union (EU). The company's commitment to these international standards ensures the production of high-quality pharmaceutical products that meet global regulatory requirements. Alembic's compliance with WHO and EU GMP standards has facilitated its entry into various international markets, reinforcing its reputation as a reliable supplier of pharmaceutical products.

CDSCO & Indian Regulatory

Alembic Pharmaceuticals Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Alembic Pharmaceuticals operates in a competitive landscape with several key players in the pharmaceutical industry. In the cardiovascular segment, Alembic's top products include Celecoxib, Losartan, and Telmisartan, with market shares of 9.1%, 3.7%, and 0.1%, respectively. In the analgesics and antipyretics category, Alembic's top product is Valsartan, holding a 5.3% market share. In the antibiotics segment, Azithromycin is Alembic's leading product with a 4.7% market share. These figures indicate Alembic's competitive positioning within these therapeutic areas.

2Key Differentiators

Alembic Pharmaceuticals distinguishes itself through its vertically integrated operations, encompassing research and development, manufacturing, and marketing of pharmaceutical products. The company's adherence to international quality standards, including WHO and EU GMP certifications, ensures the production of high-quality products. Alembic's diverse therapeutic portfolio, spanning areas such as cardiology, dermatology, and infectious diseases, enables it to address a wide range of medical needs. Additionally, the company's strategic focus on both regulated and emerging markets enhances its global presence and growth prospects.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Alembic Pharmaceuticals Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Alembic Pharmaceuticals has demonstrated a strong track record in the pharmaceutical industry, with a total export value of $127.6 million USD and 3,520 shipments across 37 products in 16 therapeutic categories. The company's top five products—Celecoxib, Losartan, Telmisartan, Valsartan, and Azithromycin—account for 41.9% of its export portfolio, indicating a diversified product range. Alembic's adherence to international quality standards and regulatory compliance further underscores its reliability as a supplier. The company's consistent export

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — Alembic Pharmaceuticals Limited

How many pharmaceutical products does Alembic Pharmaceuticals Limited export from India?

Alembic Pharmaceuticals Limited exports 37 pharmaceutical products across 16 therapeutic categories. The top exports are Celecoxib ($12.2M), Losartan ($11.1M), Telmisartan ($11.0M), Valsartan ($10.5M), Azithromycin ($8.7M). Total export value is $127.6M.

What is Alembic Pharmaceuticals Limited's total pharmaceutical export value?

Alembic Pharmaceuticals Limited's total pharmaceutical export value is $127.6M, based on 3,520 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Alembic Pharmaceuticals Limited the #1 Indian exporter?

Alembic Pharmaceuticals Limited is the #1 Indian exporter in 1 products: .

What therapeutic categories does Alembic Pharmaceuticals Limited cover?

Alembic Pharmaceuticals Limited exports across 16 therapeutic categories. The largest are Cardiovascular (37.9%, 7 products), Analgesics & Antipyretics (13.8%, 3 products), Antibiotics (12.9%, 3 products).

Get Full Alembic Pharmaceuticals Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.